Aerie Pharma (AERI) Misses Q1 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Aerie Pharma (AERI) Misses Q1 EPS by 23c

Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 5, 2021 4:01 PM EDT

First Quarter 2021 Net Revenue Per Bottle of $89, up 11.3% over Fourth Quarter 2020

First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter 2020

Significant Progress Made Across the Pipeline

Conference Call and Webcast Today, May 5th, at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal... More